Clinical Trials

Inclusion Criteria

• 30-75 years of age
• A body mass index (BMI) of 27-40 kg/m2
• Groups of healthy controls and type 2 diadetic patients will be matched for age, sex and BMI
• ADA criteria for fasting glucose will be applied
• Type 2 diabetes patients can be on lifestyle treatment, with or without monotherapy, with either metformin or sulfonylurea (SU) or combination therapy with insulin, with HbA1c <10% 
• Subjects on thiazolidinediones may be included if they agree to stop these medications for at least 3-4 weeks before study visits
• All women of childbearing potential will have a negative pregnancy test within 24 hours of the study visit
• Subjects meeting enrollment criteria on metformin and/or sulfonylurea will be asked to withdraw these drugs for 2 weeks prior to study visit and to monitor their fingerstick glucoses regularly during this period
• Subjects on long acting insulin will stop their insulin 24 hours before study admit day and continue short acting insulin as needed

Exclusion Criteria

• A history of sleep disorders, to minimize confounding the outcome variables
• Type 2 diabetics with microvascular or macrovascular complications (apart from mild background retinopathy)
• Sleep related disorders